Literature DB >> 18093813

Time and chemotherapy treatment trends in the treatment of elderly patients (age>or=70 years) with non-small cell lung cancer.

M E R O'Brien1, T Yau, J Coward, S Hughes, P Papadopoulos, S Popat, A Norton, S Ashley.   

Abstract

AIMS: Palliative chemotherapy in non-small cell lung cancer (NSCLC) has been established since 1995 and little chemotherapy treatment was given to these patients before 1990. This retrospective study investigates the treatment outcome of elderly patients (age>or=70 years) with NSCLC over the past 13 years in a large UK cancer centre.
MATERIALS AND METHODS: A comparison of all-cause survival between the time periods 1990-1994, 1995-1999 and 2000-2004 was adjusted for age, gender, stage and performance status. A comparison of survival was also made between three age groups: 70-74, 75-79 and 80+ years.
RESULTS: Between 1990 and 2004, 302 patients>or=70 years had NSCLC. There were differences in age and performance status between the time periods. There was no improvement in median survival between the three time periods (P=0.6). There was little difference in outcome between the three age cohorts.
CONCLUSIONS: The analysis shows that there has been no significant improvement in survival for elderly patients with advanced lung cancer treated with chemotherapy in the past 13 years.

Entities:  

Mesh:

Year:  2008        PMID: 18093813     DOI: 10.1016/j.clon.2007.11.007

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  2 in total

1.  Chemotherapy Near the End of Life for Chinese Patients with Solid Malignancies.

Authors:  Jin Sheng; Ya-Xiong Zhang; Xiao-Bo He; Wen-Feng Fang; Yun-Peng Yang; Gui-Nan Lin; Xuan Wu; Ning Li; Jing Zhang; Lin-Zhu Zhai; Yuan-Yuan Zhao; Yan Huang; Ning-Ning Zhou; Hong-Yun Zhao; Li Zhang
Journal:  Oncologist       Date:  2016-10-27

2.  Neutrophil to lymphocyte ratio in the pre-treatment phase of final-line chemotherapy predicts the outcome of patients with recurrent ovarian cancer.

Authors:  Keiichiro Nakamura; Takeshi Nagasaka; Takeshi Nishida; Tomoko Haruma; Chikako Ogawa; Tomoyuki Kusumoto; Noriko Seki; Yuji Hiramatsu
Journal:  Oncol Lett       Date:  2016-05-04       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.